CVR 45367282Private limited company (ApS)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)København NFounded 30 Jan 2025
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Synuca Therapeutics ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
2
CVR, Aug 2026
+1 (+100%) over 12 months
Gross profit
-256.4K
EUR, annual report 2025
Result
-272.8K
EUR, annual report 2025
Equity
-267.5K
EUR, annual report 2025
CLAUS OLESEN HOLDING ApSCVR 32082599, 25% to under 33.3% of capital and votes, since 30 Jan 2025
BODD ApSCVR 39130009, 25% to under 33.3% of capital and votes, since 30 Jan 2025
and 2 moreOperating company
Dandex estimate: 2 employees registered in 2026William Brownsince 30 Jan 2025
Lasse Reimersince 30 Jan 2025
CVR 3208259925% to under 33.3% of capital and votessince 30 Jan 2025
CVR 3913000925% to under 33.3% of capital and votessince 30 Jan 2025
CVR 4536666915% to under 20% of capital and votesnotified 3 Jun 2026since 30 Jan 2025
CVR 4536704515% to under 20% of capital and votesnotified 3 Jun 2026since 30 Jan 2025
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
Decided by Dandex with fixed rules from CVR and the filed annual reports, not registered by the company. Each label links to its definition.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
30 Jan 2025 to 12 Nov 2026.
Aug 2026, monthly: 2 employees, 2 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| FTE | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 2 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's own headcount as CVR records it, not the annual report's average, which may cover a group. Monthly Mar 2025 to Aug 2026.
Latest Aug 2026, published 21 Oct 2026. Source: CVR employment series (Årsbeskæftigelse, Kvartalsbeskæftigelse, Månedsbeskæftigelse).
| Metric | 2025 |
|---|---|
| Gross profit | -256 |
| Operating profit | -325 |
| Result for the year | -273 |
| Equity | -267 |
| Total assets | 345 |
| Employees (average) | 1 |
| Credit metrics (Dandex calculations) | |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. |
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. |
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. |
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. |
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. |
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. |
EUR thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group. 2025 covers 11 months (30 Jan to 31 Dec 2025).
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages. Gearing and interest coverage are multiples. Rows marked Pro hold a value in the Pro plan. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
Annual report 2025
30 Jan 2025 to 31 Dec 2025, published 29 Jun 2026
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The rows marked Pro on this page hold values in the Pro plan. For Synuca Therapeutics ApS, that is:
Have Pro? Sign in to see the values on this page.
Each registered value from the day it took effect, newest first.
From CVR, read 12 Nov 2026. Text such as the signing rule and purpose is shown as registered.
5 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Kapitalforhøjelsen er besluttet den 29.05.2026.
kr. 2.105,25, indbetalt kontant, kurs 100,00.
Kapitalen udgør herefter kr. 42.105,25.
Bestyrelse:
Tiltrådte:
Anker Gunvald Lundemose, (formand), den 29.06.2026, Claus Elsborg Olesen, den 29.06.2026, Lasse Reimer, den 29.06.2026.
Vedtægter ændret: 29.06.2026
Vedtægter ændret: 29.05.2026
Stiftelsesdato: 30.01.2025.
Virkningsdato: 30.01.2025.
Seneste vedtægtsdato: 30.01.2025.
Kapital:
kr. 40.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 40.000,00 til kurs 100,00, fuldt indbetalt.
Stiftere:
CVR-NR. 32082599 CLAUS OLESEN HOLDING ApS, Lyngsiesvej 18, 8230 Åbyhøj, den 30.01.2025, CVR-NR. 39130009 BODD ApS, c/o William Dalby Brown, Kåstrupvej 84, 4400 Kalundborg, den 30.01.2025, CVR-NR. 45366669 PHJ 2025 Holding ApS, Junovej 23, 8270 Højbjerg, den 30.01.2025, CVR-NR. 45367045 Raul Holding ApS, Lindealle 5, 8740 Brædstrup, den 30.01.2025.
Direktion:
William Brown, den 30.01.2025, Lasse Reimer, den 30.01.2025.
Selskabet tegnes af to direktører i forening eller af den samlede direktion
Revision:
CVR-NR. 30700228 EY Godkendt Revisionspartnerselskab, Værkmestergade 25, 8000 Aarhus C, den 30.01.2025.
Første regnskabsår:
30.01.2025 - 31.12.2025.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at drive virksomhed med forskning og udarbejdelse af stoffer, herunder til medicinalindustrien, samt enhver i forbindelse hermed stående virksomhed
2 registered in CVR.
P-number 1031035429Ole Maaløes Vej 3, 2200 København N
P-number 1031792785Høegh-Guldbergs Gade 10, 8000 Aarhus C
